STAT44%
Drug metabolism AI competition results show that bigger may not always be better 65%
By Brittany Trang82%
7/14/2026, 8:30:00 AM
BS Summary: This article contains 16 faulty reasoning types, including Biased Writer Voice, Optimism Bias, and False Dilemma, with Hasty Generalization as the most egregious example at 28.9% saturation with 61 hits. Analysis detected 569 faulty-reasoning hits from 211 analyzed words, generating a BS Score of 58.9% and a BS Rank of 65% (7,829 of 21,886 articles). This article is worse (more manipulative) than 64.20% of the article peer group.
In 2020, the CASP competition vaulted AlphaFold to prominence and a Nobel Prize.
But the era of people being impressed by an artificial intelligence model correctly predicting the structure of a protein — once a challenge many experts didn’t think would be solved in their lifetime — is over.
Now drug developers want AI that can solve their big problems, like discerning whether the body is going to attack a drug candidate and render it useless.
One such example is the pregnane X receptor, or PXR.
When activated, PXR increases the production of an enzyme that specifically breaks down foreign organic molecules — such as drug molecules — so the body can dispose of them.
The specific enzyme that PXR regulates can metabolize approximately 50% of all marketed drugs.
Most drug development campaigns only discover whether candidates trip this sensor late in the game, forcing drug developers to go back to the drawing board.
But if an AI model could reliably predict whether a given drug candidate will activate the PXR receptor, it could fix a lot of problems that present hurdles for new potential drugs, including the drug exiting the body too fast or creating drug–drug interactions.
Speakers
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.